Lost opportunities: the underutilization of castrate-resistant prostate cancer treatment in real-world settings
Authors:
Open Access
- 1 September 2024
- journal article
- research article
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 13 (9) , 1786-1794
Abstract
Background: Various treatment regimens are now available for metastatic castrate-resistant prostate cancer (CRPC). This work evaluates the real-world prescription patterns of CRPC in a large tertiary care center and the factors influencing them. Methods: Health records of 330 patients with de novo metastatic hormone-sensitive prostate cancer (HSPC), treated and progressed to CRPC between 2016 and 2020, were reviewed from a prospective uro-oncological database. We studied their demographics, medical co-morbidities, treatment utilization patterns before and after progression to CRPC, and survival outcomes. Results: The median age was 74 years [interquartile range (IQR), 67–80 years] at diagnosis of CRPC. At CRPC, beyond androgen deprivation therapy (ADT) monotherapy, 70.3% (n=232) of patients received at least one additional line, 21.5% (n=71) received two lines, and 5.5% (n=18) received three lines of systemic treatments. As first-line treatment, novel hormonal agents (NHAs) were the most prescribed at 57.6% (n=190). The likelihood of receiving treatment was associated with age vs. 17 months, OR 1.72, PConclusions: More than one in four patients do not receive any additional treatment line beyond ADT monotherapy and have worse survival outcomes. Health status, prescribing physician, and treatment at HSPC appear to affect prescription patterns at the CRPC stage.Keywords
This publication has 36 references indexed in Scilit:
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate CancerNew England Journal of Medicine, 2017
- Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysisProstate Cancer and Prostatic Diseases, 2017
- Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL StudyEuropean Urology, 2017
- Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate CancerJAMA Oncology, 2016
- The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerEuropean Urology, 2016
- Risk of selection bias in randomised trialsTrials, 2015
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerNew England Journal of Medicine, 2015
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate CancerNew England Journal of Medicine, 2004
- Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institutionEuropean Journal of Cancer, 1996